Security
Cumberland Pharmaceuticals Inc. Common Stock · CPIX
CPIXNASDAQCommon stockCurrentCIK 1087294Updated Oct 27, 2026
CPIX price & chart
Loading TradingView…
NASDAQ:CPIX on TradingView ↗About the company
Cumberland Pharmaceuticals Inc. is a Nashville-based biopharmaceutical company focused on developing new therapies for rare diseases. The company is advancing a late-stage pipeline of product candidates through a series of late stage clinical studies. The treatments are being developed across multiple therapeutic areas to address serious patient conditions that represent unmet medical needs. Cumberland's Phase 2 clinical programs are evaluating ifetroban in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Cancer Metastasis.
In the news
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement ↗
--> CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE News provided by Cumberland Pharmaceuticals Inc. Oct 28, 2025, 16:05 ET Share this article Share to X Share this article Share to X Cumberland Pharmaceuticals Logo (PRNewsFoto/Cumberland Pharmaceuticals Inc.) NASHV ↗
Seeking Alpha
Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy - Slideshow ↗
Cumberland Pharmaceuticals: The FDA's Phase 3 Question Is Hard To Ignore ↗
At a glance: stocks gapping down premarket ↗
SEC disclosures
CUMBERLAND PHARMACEUTICALS INC files 8-K/A ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Regulation FD Disclosure
Items 7.01
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Completion of Acquisition or Disposition of Assets · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 1.01, 1.02, 2.01, 5.02, 8.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
DEFM14A filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 65,898,560Source | 76,747,513Source | 87,750,944Source | 62,879,694Source | 67,907,149Source | 78,519,175Source | 69,935,878Source | 81,509,518Source | 76,823,992Source | 75,583,410Source | 81,776,075Source | 92,925,158Source |
| Property, Plant and Equipment, NetUSD | 293,375Source | 312,031Source | 377,439Source | 248,808Source | 297,793Source | 337,089Source | 298,740Source | 369,499Source | 264,724Source | 277,365Source | 367,903Source | 284,039Source |
| GoodwillUSD | 914,000Source | 914,000Source | 914,000Source | — | 914,000Source | 914,000Source | 914,000Source | 914,000Source | 914,000Source | 914,000Source | 914,000Source | 914,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,196,745Source | 17,464,754Source | 18,507,965Source | 3,862,402Source | 16,087,281Source | 17,336,446Source | 15,108,413Source | 18,548,485Source | 11,444,693Source | 17,964,184Source | 18,321,624Source | 19,757,970Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 10,430,602Source | 11,310,625Source | 12,620,120Source | 13,419,594Source | 10,316,911Source | 11,619,763Source | 10,487,925Source | 10,647,267Source | 16,944,780Source | 11,701,466Source | 9,758,176Source | 13,163,681Source |
| Inventory, NetUSD | 2,934,723Source | 4,509,669Source | 8,670,548Source | 29,935Source | 3,222,872Source | 4,302,159Source | 4,098,859Source | 4,327,526Source | 6,225,518Source | 3,999,995Source | 4,609,362Source | 9,863,581Source |
| Assets, CurrentUSD | 29,939,448Source | 35,236,406Source | 41,769,797Source | 33,641,145Source | 31,205,329Source | 35,581,093Source | 31,877,151Source | 36,205,951Source | 37,060,267Source | 36,452,158Source | 35,714,410Source | 45,870,210Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,377,378Source | 1,951,358Source | — | 675,993Source | 1,578,265Source | 2,322,725Source | 2,181,954Source | 2,682,673Source | 2,445,276Source | 2,786,513Source | 3,025,248Source | 3,084,978Source |
| Operating Lease, Right-of-Use AssetUSD | 7,570,452Source | 6,208,411Source | 6,711,155Source | 7,281,280Source | 7,125,408Source | 6,365,790Source | 7,177,490Source | 6,521,088Source | 8,343,832Source | 6,176,923Source | 6,674,394Source | 5,218,403Source |
| Other Assets, NoncurrentUSD | 2,986,628Source | 2,829,506Source | 2,555,638Source | 3,171,623Source | 2,850,265Source | 2,993,881Source | 2,742,299Source | 3,060,643Source | 2,973,378Source | 2,784,016Source | 2,692,921Source | 2,520,661Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 40,097,856Source | 52,278,121Source | 52,095,386Source | 45,773,246Source | 40,228,222Source | 52,486,991Source | 41,595,259Source | 54,319,966Source | 52,279,770Source | 53,037,433Source | 52,516,206Source | 56,951,152Source |
| Stockholders’ equity: | ||||||||||||
| Retained Earnings (Accumulated Deficit)USD | -25,392,367Source | -22,064,117Source | -11,193,755Source | -34,370,075Source | -23,451,603Source | -20,520,036Source | -22,710,863Source | -19,434,424Source | -26,804,059Source | -23,967,931Source | -17,488,161Source | -11,208,841Source |
| Stockholders' Equity Attributable to ParentUSD | 26,119,854Source | 24,779,086Source | 35,991,549Source | 17,438,013Source | 27,989,795Source | 26,348,990Source | 28,657,020Source | 27,489,333Source | 24,880,322Source | 22,853,494Source | 29,603,441Source | 36,266,132Source |
| Liabilities and EquityUSD | 65,898,560Source | 76,747,513Source | 87,750,944Source | 62,879,694Source | 67,907,149Source | 78,519,175Source | 69,935,878Source | 81,509,518Source | 76,823,992Source | 75,583,410Source | 81,776,075Source | 92,925,158Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 24,309,969Source | 31,087,515Source | 27,328,270Source | 35,193,138Source | 23,972,140Source | 24,756,169Source | 25,519,619Source | 26,425,380Source | 36,744,919Source | 31,621,729Source | 27,982,249Source | 28,579,832Source |
| Operating Lease, Liability, CurrentUSD | 401,445Source | 391,688Source | 334,288Source | 503,016Source | 386,077Source | 376,780Source | 371,094Source | 362,244Source | 467,774Source | 356,508Source | 348,092Source | 172,910Source |
| Accounts Payable, CurrentUSD | 13,832,497Source | 12,057,712Source | 10,818,045Source | 19,554,251Source | 13,446,531Source | 12,508,026Source | 13,927,623Source | 13,075,764Source | 18,567,546Source | 13,914,266Source | 14,037,629Source | 10,819,011Source |
| Operating Lease, Liability, NoncurrentUSD | 4,595,768Source | 4,997,212Source | 5,388,900Source | 4,211,168Source | 4,714,183Source | 5,100,260Source | 4,829,054Source | 5,200,148Source | 4,471,965Source | 4,939,739Source | 5,296,247Source | 4,586,301Source |
| Other Liabilities, NoncurrentUSD | 5,951,386Source | 6,090,722Source | 6,455,091Source | 3,981,224Source | 6,301,166Source | 6,538,970Source | 6,005,853Source | 6,610,294Source | 5,822,153Source | 6,299,795Source | 6,453,566Source | 7,585,019Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -319,150Source | -309,694Source | -335,991Source | -331,565Source | -310,868Source | -316,806Source | -316,401Source | -299,781Source | -336,100Source | -307,517Source | -343,572Source | -292,126Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | — | — | 7,518,645Source | — | — | — | — | 12,635,095Source | 12,250,955Source | 13,596,528Source | 17,587,911Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | — | — | — | — | — | 0Source | 5,100,000Source | — | — |
| Common Stock, Value, Issued | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -1,949,046Source | -1,536,969Source | -4,274,430Source | -735,207Source | -1,102,637Source | 1,248,184Source | -2,864,711Source | -6,443,715Source | -6,330,766Source | -5,650,039Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | 1,031,584Source | 4,145,201Source | 4,902,560Source | 4,935,954Source | 5,328,113Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 74,212Source | 408,320Source | 301,895Source | 365,040Source | 447,503Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | -1,213,541Source | 5,243,314Source | 1,943,290Source | -3,404,949Source | 6,115,640Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | -967,399Source | -2,242,616Source | -2,408,397Source | 23,143Source | -911,078Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | — | 3,898,517Source | 4,932,522Source | -612,186Source | 6,093,821Source | 8,453,396Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | -1,228,186Source | -4,706,497Source | 57,842Source | -105,695Source | -13,674,456Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 47,630Source | 97,903Source | 66,461Source | 281,268Source | 102,148Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | 245,868Source | 263,478Source | 579,049Source | 740,533Source | 1,053,042Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | -5,526,102Source | -6,745,516Source | 196,904Source | -7,424,472Source | -2,061,786Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | -2,855,771Source | -6,519,491Source | -357,440Source | -1,436,346Source | -7,282,846Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 15,196,745Source | 17,464,754Source | 3,862,402Source | 16,087,281Source | 17,336,446Source | 15,108,413Source | 11,444,693Source | 17,964,184Source | 18,321,624Source | 19,757,970Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 441,677Source | 569,230Source | 647,137Source | 523,161Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | -3,525Source | 15,000Source | 108,823Source | 3,300Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | 400,000Source | 300,000Source | 400,000Source | — |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | 5,362Source | 23,185Source | 28,313Source | 15,523Source | 11,237Source |
| Amortization of Intangible AssetsUSD | — | — | 1,009,598Source | 1,078,290Source | 7,151Source | 5,769Source | 1,099,857Source | 1,005,330Source | 4,034,657Source | 4,748,252Source | 8,102,648Source | 5,067,368Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | 0Source | -2,691Source | -20,256Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | -13,220Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | 0Source | 475,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,572,066Source | 2,675,380Source | 2,547,606Source | 2,657,146Source | 2,757,148Source | 2,463,008Source | 11,946,909Source | 11,126,901Source | 10,651,915Source | 10,180,120Source |
| GoodwillUSD | — | — | 914,000Source | 914,000Source | — | 914,000Source | 914,000Source | 914,000Source | 914,000Source | 914,000Source | 914,000Source | 914,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 400,000Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | 0Source | 3,343,842Source | — |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | -3,104,171Source | -2,998,172Source | — | — | -2,864,711Source | -6,443,715Source | — | -5,650,039Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | 0Source | -13,220Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 5,670Source | 11,442Source | 3,870Source | 5,671Source | 11,443Source | 5,670Source | 40,256Source | -22,669Source | 45,769Source | 68,850Source |
| Insured Event, Gain (Loss)USD | — | — | 0Source | 237,089Source | — | — | — | — | 0Source | 237,089Source | 346,800Source | 611,330Source |
| Investment Income, InterestUSD | — | — | 131,583Source | 69,190Source | 60,884Source | 127,489Source | 61,841Source | 125,709Source | 476,748Source | 334,444Source | 286,854Source | 98,405Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,940,764Source | -1,544,081Source | -4,276,377Source | -740,740Source | -1,085,612Source | 1,257,068Source | -2,836,128Source | -6,479,770Source | -6,279,320Source | -5,570,241Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -8,282Source | 7,112Source | 1,947Source | 5,533Source | -17,025Source | -8,884Source | -28,583Source | 36,055Source | -51,446Source | -79,798Source |
| Operating Lease, ExpenseUSD | — | — | 356,413Source | 342,032Source | 358,961Source | 363,583Source | 344,418Source | 354,752Source | 1,580,113Source | 1,384,083Source | 1,304,865Source | 1,159,695Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | 0Source | — | 4,715,950Source | 4,715,950Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | 0Source | — | — | — | 0Source |
| Inventory Write-down | — | — | — | — | — | — | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 8,292,362Source | 9,085,826Source | 8,801,241Source | 10,837,363Source | 9,848,849Source | 11,713,055Source | 44,521,431Source | 37,867,945Source | 39,552,507Source | 40,681,182Source |
| Cost of RevenueUSD | — | — | 988,760Source | 1,323,013Source | — | 2,011,389Source | 1,710,944Source | 1,425,714Source | 6,667,207Source | 6,585,972Source | 6,066,611Source | 9,118,521Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (Loss)USD | — | — | -1,965,260Source | -1,694,432Source | -3,160,461Source | -3,119,519Source | -1,026,688Source | 1,291,947Source | -2,791,993Source | -6,432,409Source | -9,554,661Source | -5,704,929Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -1,943,376Source | -1,525,527Source | -3,100,301Source | -2,992,501Source | -1,091,194Source | 1,253,854Source | — | -6,466,384Source | -6,284,997Source | -5,581,189Source |
| Income Tax Expense (Benefit)USD | — | — | 5,670Source | 11,442Source | 3,870Source | 5,671Source | 11,443Source | 5,670Source | 40,256Source | -22,669Source | 45,769Source | 68,850Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | -8,282Source | 7,112Source | 1,947Source | 5,533Source | -17,025Source | -8,884Source | -28,583Source | 36,055Source | -51,446Source | -79,798Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,940,764Source | -1,544,081Source | -4,276,377Source | -740,740Source | -1,085,612Source | 1,257,068Source | -2,836,128Source | -6,479,770Source | -6,279,320Source | -5,570,241Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.13Source | -0.11Source | -0.29Source | -0.05Source | -0.08Source | 0.08Source | -0.19Source | -0.46Source | -0.44Source | -0.38Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.13Source | -0.11Source | -0.29Source | -0.05Source | -0.08Source | 0.08Source | -0.19Source | -0.46Source | -0.44Source | -0.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 14,958,534Source | 14,052,754Source | 14,981,607Source | 14,960,596Source | 14,118,091Source | 14,942,522Source | 14,854,619Source | 14,060,272Source | 14,298,774Source | 14,563,592Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 14,958,534Source | 14,052,754Source | 14,981,607Source | 14,960,596Source | 14,118,091Source | 15,259,824Source | 14,854,619Source | 14,060,272Source | 14,298,774Source | 14,563,592Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 1,009,598Source | 1,078,290Source | 7,151Source | 5,769Source | 1,099,857Source | 1,005,330Source | 4,034,657Source | 4,748,252Source | 8,102,648Source | 5,067,368Source |
| Costs and ExpensesUSD | — | — | 10,257,622Source | 10,780,258Source | 3,326,919Source | 3,500,316Source | 10,875,537Source | 10,421,108Source | 47,313,424Source | 44,300,354Source | 49,107,168Source | 47,715,878Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 40,000Source | -22,669Source | 45,769Source | -68,850Source |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | -13,220Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | 0Source | 475,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,572,066Source | 2,675,380Source | 2,547,606Source | 2,657,146Source | 2,757,148Source | 2,463,008Source | 11,946,909Source | 11,126,901Source | 10,651,915Source | 10,180,120Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 400,000Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | -3,104,171Source | -2,998,172Source | — | — | -2,864,711Source | -6,443,715Source | — | -5,650,039Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | — | -0.21Source | -0.2Source | — | — | — | — | — | -0.38Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | — | -0.21Source | -0.2Source | — | — | — | — | — | -0.38Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | 0Source | -13,220Source | — | — | — |
| Interest ExpenseUSD | — | — | 109,699Source | 137,374Source | 724Source | 471Source | 126,347Source | 163,802Source | 495,990Source | 605,508Source | 667,861Source | 585,995Source |
| Investment Income, InterestUSD | — | — | 131,583Source | 69,190Source | 60,884Source | 127,489Source | 61,841Source | 125,709Source | 476,748Source | 334,444Source | 286,854Source | 98,405Source |
| Operating Lease, ExpenseUSD | — | — | 356,413Source | 342,032Source | 358,961Source | 363,583Source | 344,418Source | 354,752Source | 1,580,113Source | 1,384,083Source | 1,304,865Source | 1,159,695Source |
| Other IncomeUSD | — | — | — | 0Source | — | — | 0Source | — | — | 0Source | 2,828,871Source | 0Source |
| Research and Development ExpenseUSD | — | — | 1,253,367Source | 1,306,095Source | 772,162Source | 837,401Source | 1,059,187Source | 1,295,076Source | 5,566,498Source | 4,816,206Source | 5,834,229Source | 6,688,924Source |
| Selling and Marketing ExpenseUSD | — | — | 4,433,831Source | 4,397,480Source | — | 4,223,647Source | 4,248,401Source | 4,231,980Source | 19,098,153Source | 17,023,023Source | 18,451,765Source | 16,660,945Source |
Filing attachments
tm2619330d1_ex99-1.htm · 8-K · 2026-07-01
EX-99.1 3 tm2619330d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex $100 million Transaction Follows Cumberland Shareholder Approval Strengthens Cumberland’s Focus on Rare Disease Pipeline NASHVILLE, Tenn. (July 1, 2026) - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. (“Apotex”), the largest Canadian-based pharm…
Read attachment ↗tm2619330d1_ex99-2.htm · 8-K · 2026-07-01
EX-99.2 4 tm2619330d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 UNAUDITED PRO FORMA FINANCIAL INFORMATION The following unaudited pro forma condensed consolidated balance sheet data as of March 31, 2026, is presented to show how the Transaction might have affected the historical financial statements of the Company if the Transaction had occurred on March 31, 2026. The following unaudited pro forma condensed consolidated statements of operations data for the year ended December 31, 2024, Decembe…
Read attachment ↗tm2611622d1_ex99-1.htm · 8-K · 2026-04-23
EX-99.1 4 tm2611622d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex Transaction unlocks $100 million in value for Cumberland Sharpens focus on Orphan Drug Candidates to address Unmet Medical Needs NASHVILLE, Tenn. (April 23, 2026) - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apot…
Read attachment ↗ex991-fdafasttrackfordmdx2.htm · 8-K · 2026-02-04
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program NASHVILLE, Tenn. (February 4, 2026) - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy ("DMD") p…
Read attachment ↗